CytoReason vs Tarsier Pharma
CytoReason vs Tarsier Pharma, compared side by side on 20 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: CytoReason is on 68/100 and Tarsier Pharma on 47/100.
Where each one leads
CytoReason
- our overall score: 68/100 against 47/100
- domain rating: 40/100 against 34/100
- headcount: 116 against 12
- headcount growth: +13.7% against +2.8%
- funding raised: $128M against $5.0M
- LinkedIn following: 12,830 against 1,582
Tarsier Pharma
Leads on none of the measures we hold for both companies.
At a glance
| Measure | CytoReason | Tarsier Pharma |
|---|---|---|
| What it is | Develops a computational model of the human body for drug discovery and development. | Clinical-stage company developing novel treatments for ocular inflammatory blinding diseases. |
| Category | Healthcare, Drug Discovery, Clinical Development, Biomarkers | Healthcare, Disease Treatment, Vision Impairment, Biotech |
| Sells toBusiness model | B2B | B2B |
| Offering | Software | Services |
| Founded | 2016 | 2016 |
| Headquarters | Tel Aviv, Israel | Tel Aviv, Israel |
| Status | Active | Active |
Size, funding and growth
| Measure | CytoReason | Tarsier Pharma |
|---|---|---|
| Employees | 116 | 12 |
| Headcount growthLast 12 months | +13.7% | +2.8% |
| Total funding | $128M | $5.0M |
| Latest round | Series B | Series B |
| LinkedIn followers | 12,830 | 1,582 |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | CytoReason | Tarsier Pharma |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 68/100 | 47/100 |
| Traction | 60/100 | 45/100 |
| Team | 70/100 | 20/100 |
| Search visibility | 30/100 | 31/100 |
| Quality | 78/100 | 58/100 |
| Agent readinessHow well an AI agent can read and act on the site | F (21/100) | F (21/100) |
| Domain ratingLink authority, 0-100 | 40/100 | 34/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | CytoReason | Tarsier Pharma |
|---|---|---|
| CDN | Not detected | Cloudflare |
| CMS | Not detected | WordPress |
| Frameworks | Not detected | Jquery |
| Analytics | Segment | Google Analytics 4 |
CytoReason vs Tarsier Pharma: common questions
Which is better, CytoReason or Tarsier Pharma?
On our 0-100 score CytoReason rates higher (68/100 against 47/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 20 data points above: read the rows that match what you are buying for.
How do CytoReason and Tarsier Pharma compare on the numbers?
CytoReason leads on our overall score (68/100 against 47/100), domain rating (40/100 against 34/100), headcount (116 against 12), headcount growth (+13.7% against +2.8%), funding raised ($128M against $5.0M), LinkedIn following (12,830 against 1,582).
Read the full CytoReason review and pricing or the Tarsier Pharma review and pricing. You can also browse other CytoReason alternatives we track.